Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Blueprint Medicines revenue
Blueprint Medicines's revenue is $508.8 million.
What is Blueprint Medicines's revenue?
- Blueprint Medicines's revenue growth from 2015 to 2024 is 4,363.37%.
- Blueprint Medicines has 495 employees, and the revenue per employee ratio is $1,027,927.
- Blueprint Medicines's peak quarterly revenue was $745.1M in 2020(q3).
- Blueprint Medicines peak revenue was $793.7M in 2020.
- Blueprint Medicines annual revenue for 2023 was 249.4M, 22.22% growth from 2022.
- Blueprint Medicines annual revenue for 2024 was 508.8M, 104.04% growth from 2023.
On this page
Zippia finds jobs where you're a top candidate and applies on your behalf.
Blueprint Medicines historical revenue
Blueprint Medicines's peak revenue was $793.7M in 2020. The peak quarterly revenue was $745.1M in 2020(q3).
Blueprint Medicines's revenue increased from $11.4m in 2015 to $508.8M currently. That's a 4,363.37% change in annual revenue.
Blueprint Medicines annual revenue
Blueprint Medicines annual revenue over time
| Fiscal year / year | Blueprint Medicines revenue |
|---|---|
| 2015 | $11.4M |
| 2016 | $27.8M |
| 2017 | $21.4M |
| 2018 | $44.5M |
| 2019 | $66.5M |
| 2020 | $793.7M |
| 2021 | $180.1M |
| 2022 | $204.0M |
| 2023 | $249.4M |
| 2024 | $508.8M |
How accurately did Blueprint Medicines' revenue projections match actual performance?
Blueprint Medicines annual growth
Blueprint Medicines saw the greatest revenue growth in 2020, when revenue increased by 1,093.37%.
Blueprint Medicines had the lowest revenue growth in 2021, when revenue changed by -77.31%.
Blueprint Medicines annual growth rate over time
| Year | Blueprint Medicines growth |
|---|---|
| 2016 | 144%↑ |
| 2017 | -23%↓ |
| 2018 | 108%↑ |
| 2019 | 49%↑ |
| 2020 | 1093%↑ |
| 2021 | -77%↓ |
| 2022 | 13%↑ |
| 2023 | 22%↑ |
| 2024 | 104%↑ |
Blueprint Medicines quarterly revenue over time
- Q1
- Q2
- Q3
- Q4
Blueprint Medicines quarterly growth rate over time
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2015 | $652,000 | $2.7M | $3.4M | $4.6M |
| 2016 | $6.9M | $7.1M | $6.2M | $7.7M |
| 2017 | $5.8M | $5.9M | $8.1M | $1.6M |
| 2018 | $954,000 | $41.4M | $1.1M | $1.0M |
| 2019 | $730,000 | $5.1M | $9.1M | $51.5M |
| 2020 | $6.2M | $8.3M | $745.1M | $34.1M |
| 2021 | $21.6M | $27.3M | $24.2M | $107.0M |
| 2022 | $62.7M | $36.5M | $66.0M | $38.8M |
| 2023 | $63.3M | $57.6M | $56.6M | $72.0M |
| 2024 | $96.1M | $138.2M | $128.2M | $146.4M |
Blueprint Medicines jobs nearby
Do you work at Blueprint Medicines?
Did Blueprint Medicines meet its revenue projections?
Blueprint Medicines financial information
| CEO | Jeffrey W. Albers |
| Company Type | Public |
| Employees Number | 495 |
| Date Founded | 2011 |
| Headquarters | Cambridge, Massachusetts |
| Number of Locations | 2 |
| Revenue | $508.8M |
| Net Income | -$557,517,000 |
| Gross Proft | $488.7M (2024) |
| PE Ratio | -37.58 |
| Tax Rate | -0.0% |
| Market Capitalization | $2.5B |
| Total Assets | $1,349,902,000 |
| Ticker | BPMC |
Blueprint Medicines jobs you might like
Blueprint Medicines financing
Blueprint Medicines received early financing of $40.0M on 2011-04-11.
| Series | Round size | Date |
|---|---|---|
| Series A | $40M | 04/2011 |
| Series B | $25M | 01/2014 |
| Series C | $50M | 11/2014 |
| Post Ipo Equity | $134.5M | 12/2016 |
| Post Ipo Equity | $215.6M | 03/2017 |
| Post Ipo Equity | $325.5M | 12/2017 |
| Post Ipo Equity | $327.2M | 03/2019 |
Blueprint Medicines investors
| Investors | Security type |
|---|---|
| Third Rock Ventures | Series A |
| F Prime Capital | Series A |
| Fidelity Biosciences | Series B |
| Nextech Invest | Series B |
| Third Rock Ventures | Series B |
| Biotechnology Value Fund | Series B |
| F Prime Capital | Series B |
| Casdin Capital | Series B |
| Partner Fund Management | Series C |
| Fidelity Biosciences | Series C |
| Redmile Group | Series C |
| Wellington Management | Series C |
| Tavistock Group | Series C |
| Perceptive Advisors | Series C |
| Sabby Capital | Series C |
| Third Rock Ventures | Series C |
| Nextech Invest | Series C |
| Cowen Inc. | Series C |
| RA Capital Management | Series C |
| Casdin Capital | Series C |
Blueprint Medicines competitors
Blueprint Medicines's top competitor, EMD Serono, earned an annual revenue of $400.0M.
Blueprint Medicines's smallest competitor is Channing Ross with revenue of $320.0K last year.
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Syros Pharmaceuticals | - | $9.9M | 124 | - |
| ReproSource | - | $3.8M | 36 | - |
| EMD Serono | - | $400.0M | 1,000 | - |
| Mendel Biotechnology | - | $13.0M | 125 | - |
| Lankenau Institute for Medical Research | - | $8.9M | 125 | - |
| Ophthotech | - | $210.0M | 58 | - |
| Channing Ross | - | $320,000 | 4 | - |
| Donald Danforth Plant Science Center | - | $17.2M | 100 | - |
| Molecular Science | - | $1.2M | 19 | - |
| Stratos Genomics | - | $8.0M | 75 | - |
Search for jobs
Related company revenues
Working at related companies
Related company jobs
Blueprint Medicines highest paying jobs
Zippia gives an in-depth look into the details of Blueprint Medicines, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Blueprint Medicines. The employee data is based on information from people who have self-reported their past or current employments at Blueprint Medicines. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Blueprint Medicines. The data presented on this page does not represent the view of Blueprint Medicines and its employees or that of Zippia.
Blueprint Medicines may also be known as or be related to BLUEPRINT MEDICINES CORP, Blueprint Medicines, Blueprint Medicines Corp, Blueprint Medicines Corp. and Blueprint Medicines Corporation.